Vulcan Two Group plc acquires CloudRx, Hyperdrug and Webmed for GBP 40,000,000 (2026)

Deal facts

Buyer: Vulcan Two Group plc
Target: CloudRx, Hyperdrug and Webmed
Deal value: GBP 40,000,000
Announced: 19 March 2026
Status: Completed
Sector: Healthcare
Country: United Kingdom
Consideration: shares

Sources

What we know

Vulcan Two Group plc has agreed to acquire CloudRx, Hyperdrug and Webmed in a strategic acquisition within the ePharmacy sector. The transaction, announced and completed on 19 March 2026, involves consideration in the form of shares. The reported deal value stands at 40 million GBP, though the specific valuation methodology remains undisclosed. This acquisition brings three distinct online pharmacy brands under a single corporate umbrella in the United Kingdom.

The combined entity now operates across the UK market with an expanded portfolio of digital health services. All regulatory requirements for the transaction have been satisfied, allowing the deal to proceed without further delay. The management teams of the acquired brands will integrate into the wider group structure to drive operational synergies. The transaction is now fully completed and effective as of the announcement date.

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

19 Mar 2026CompletedClosed
Vulcan Two Group plc to acquire CloudRx, Hyperdrug and Webmed
{ "headline": "Completion of Acquisitions and Re-Admission", "issuer": "Vulcan Two Group PLC (VUL)", "announcement_date": "2026-03-19T08:12:00", "category_code": "Completion of Acquisition", "body": "Disclaimer* \n\n 19 March 2026 \n\n Vulcan Two Group plc \n\n (the \"Company\") \n\n \n\n Completion of Acquisitions, \n\n Completion of Placing and \n\n Re-admission to trading \n\n \n\
LSE RNS

OpinionExit Mode editorial

We see a clear shift in the ePharmacy sector as Vulcan Two Group plc finalises its acquisition of CloudRx, Hyperdrug and Webmed. This completed deal, announced on 19 March 2026, brings three distinct digital health assets under one UK-based roof for a total consideration of 40 million GBP. The structure is straightforward yet significant: the entire value is settled in shares. This choice of consideration signals a long-term alignment between the buyer and the sellers, moving beyond a simple cash exit to a shared equity future.

For the SME founder reading this, the mechanics of a share-only deal carry specific weight. It removes immediate liquidity but introduces exposure to the buyer's future performance and governance. In a sector as tightly regulated as ePharmacy, this structure often reflects a desire to retain key talent and ensure continuity of service. The lack of cash consideration means the transaction likely bypasses certain immediate tax events that a cash deal would trigger, though it does not eliminate the need for careful tax planning on the share exchange. The strategic nature of the acquisition suggests the buyer views these platforms as integral to its own growth rather than mere add-ons.

Regulatory clearance in this space is rarely simple. While the deal is marked as completed, any merger of this scale in the UK digital health space would have required scrutiny regarding competition and consumer protection. The Competition and Markets Authority typically reviews such consolidations to ensure they do not stifle innovation or harm patient access. Furthermore, the Financial Conduct Authority may have examined the prospectus implications given the public nature of the buyer. These layers of oversight are not obstacles but rather markers of a robust, compliant transaction that has navigated the necessary legal frameworks.

The most immediate action for any founder considering a similar path is to model the dilution and lock-up periods inherent in a share-based exit before signing. Do not rely on the headline value alone. Instead, request the specific vesting schedule and any post-completion trading restrictions attached to the new shares. This week, ask your advisers to draft a scenario analysis showing your effective ownership percentage if the buyer's share price drops by twenty per cent within the first year. This single calculation will reveal whether the deal truly offers the security you need or merely defers the risk.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from Vulcan Two Group plc All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

27 April 2026CompletedHealthcare

BIOMARIN PHARMACEUTICAL INC to acquire Amicus

BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

Buyer history